Why Insmed’s latest respiratory moves are drawing fresh investor attention

Insmed (INSM) is back in focus after partnering with EMBARC on a large, long term brensocatib study in European bronchiectasis patients, while attention also builds around upcoming TPIP lung drug data.

Those respiratory headlines are landing against a mixed share price backdrop for Insmed, with the stock up 9.05% on a 7 day share price return but still down 28.10% on a 90 day share price return. At the same time, the 3 year total shareholder return above 4x and a positive 1 year total shareholder return suggest longer term holders have seen very strong gains even as recent momentum has cooled.

If Insmed’s respiratory pipeline has caught your eye, this could be a good moment to widen your search using the 39 healthcare AI stocks

With Insmed shares down 41.02% year to date, yet trading at a 69% discount to one intrinsic value estimate and an 88.62% discount to the average analyst target, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 47% Undervalued

Analysts following Insmed see a fair value of about $197 per share, compared with the recent $104.47 close, which sets up a wide valuation gap for investors to interrogate.

The analysts have a consensus price target of $197.14 for Insmed based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $243.0, and the most bearish reporting a price target of just $140.0.

Want to see what sits behind that near doubling from the current price? Revenue expansion, margin swing, and a rich future earnings multiple all contribute to this fair value case. The detailed narrative lays out how those moving parts are expected to interact over time.

The most widely followed Insmed narrative builds its view using a high assumed revenue growth path, a shift from today’s heavy losses toward double digit profit margins, and a future P/E that stands well above typical biotech levels. All of this is discounted back at about 7% to reach the $197 fair value, so if any of those inputs look stretched or conservative to you, it is worth stress testing the scenario against your own expectations.

Result: Fair Value of $197 (UNDERVALUED)

However, Insmed’s story could change quickly if regulators delay brensocatib approvals or if payers push back on pricing and reimbursement assumptions that underpin current forecasts.

Another view on Insmed’s valuation

While our DCF model suggests Insmed is trading at a 69.1% discount to an estimate of future cash flow value at about $338.56 per share, that output depends heavily on long run growth, margins, and discount rate choices. If those inputs prove too optimistic, today’s discount could look much smaller.

Next Steps

If the mixed message around Insmed has you unsure, this is the time to move quickly, review the data for yourself, and weigh both sides of the story using our breakdown of 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Insmed?

If Insmed has sharpened your interest, do not stop here. Broader opportunity often sits with stocks that have different risk profiles, income streams, or balance sheet strength.

Use the Simply Wall St Screener to quickly surface fresh ideas before other investors catch on.

• Target potential value opportunities by scanning companies that trade below intrinsic value estimates with the 44 high quality undervalued stocks
• Strengthen the defensive side of your portfolio by filtering for companies with robust finances using the solid balance sheet and fundamentals stocks screener (48 results)
• Spot tomorrow's potential standouts early by reviewing a screener containing 18 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.